CYP cynata therapeutics limited

Open quesation - Is Kilian as CEO stewarting existing...

  1. 2,282 Posts.
    lightbulb Created with Sketch. 1205
    Open quesation - Is Kilian as CEO stewarting existing shareholders funds wisely?

    I think not. Because I think he gave options to the Chief Business Officer that would see the Chief Business Officer get a windfall if the Chief Business Officer did nothing but wait until the Sculptor trial reports.

    If nothing was spent on anything else a positive Sculptor trial should see a share price above 29 cents.

    I don't think its fair or proper to incentive a new hire by raiding the value paid for by shareholders already.

    Can the new hire actually help with making partnership deals? What is his value proposition (i.e what does he pitch to a potential partner at this point - is it just what is in the investor preso?) Would Kilian recognize a good deal if he saw it?

    What evidence is there - what has Kilian ever done, what vision has he ever articulated to distinguish himself from Ross? So far not being Ross (not having Ross's legacy - like in the Kohler interview - where Ross suggested only low ball offers would be consistent with a bidder in their right mind at that time) seems to be Kilian's only distinguishing feature that I can see.

 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
16.0¢
Change
-0.005(3.03%)
Mkt cap ! $36.15M
Open High Low Value Volume
16.5¢ 16.5¢ 16.0¢ $73.23K 457.5K

Buyers (Bids)

No. Vol. Price($)
1 31250 16.0¢
 

Sellers (Offers)

Price($) Vol. No.
16.5¢ 27550 2
View Market Depth
Last trade - 16.10pm 23/06/2025 (20 minute delay) ?
CYP (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.